Starting in June, Colorado’s Medicaid agency will cover a breakthrough hepatitis C drug on a case-by-case basis, while it decides who will qualify for the potentially life-saving drug, and who will not.
For the first time in decades, researchers trying to develop a vaccine for malaria have discovered a new target they can use to attack this deadly and common parasite.
Finding a target for attack is a far cry from having a vaccine. And the history of malaria vaccines is littered with hopeful ideas that didn't pan out. Still, researchers in the field welcome this fresh approach.
Most experimental drugs fail before they make it through all the tests required to figure out if they actually work and if they're safe. But some drugs get fairly far down that road, at the cost of hundreds of millions of dollars, based on poorly conducted studies at the outset.
Medical researchers reviewing this sorry state of affairs say the drug-development process needs serious improvement.
Later this spring, allergy sufferers will have access to a new form of help: a pill that can replace allergy shots. But the pill works only for grass allergies, and it's not clear how much it's going to cost.
The Food and Drug Administration just approved Oralair, the first sublingual allergy immunotherapy tablet for use in the United States. That's how regulators describe a pill that you stick under your tongue to tamp down your immune system.
Federal regulators this month opened a new era in the treatment of a deadly liver virus that infects three to five times more people than HIV. Now the question is: Who will get access to the new drug for hepatitis C, and when?
The drug Sovaldi will cost $1,000 per pill. A typical course of treatment will last 12 weeks and run $84,000, plus the cost of necessary companion drugs. Some patients may need treatment for twice as long.